-
December 23, 2022
Pharmaceuticals
PDF326 KB
Humanized Anti-CD20 Monoclonal Antibody Gazyva Approved for Additional Indication of Chronic Lymphocytic Leukemia
-
December 20, 2022
R & D
PDF230 KB
NS-018, Treatment for Myelofibrosis under development in overseas received Orphan Drug Designation from the U.S. FDA
-
November 16, 2022
Pharmaceuticals
PDF275 KB
Launch of Fintepla® (fenfluramine) for the Treatment of Seizures Associated with Dravet syndrome in Japan
-
November 10, 2022
Management & Finance
Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2022
-
November 10, 2022
Management & Finance
PDF280 KB
Revision of Performance Projection, Dividend of Surplus (Interim Dividend) and Revision of Year-end Dividend Forecast
-
October 26, 2022
Management & Finance
PDF118 KB
Revision of Performance Projection
-
October 24, 2022
R & D
PDF269 KB
VILTEPSO® (viltolarsen) injection: Four-Year Clinical Trial Data Presented at the World Muscle Society 2022 Conference
-
October 03, 2022
R & D
PDF261 KB
VILTEPSO® (viltolarsen) injection Four-Year Clinical Trial Data to be Presented at the World Muscle Society 2022 Conference
-
September 26, 2022
Pharmaceuticals
PDF286 KB
Fintepla® (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet syndrome
-
August 09, 2022
Management & Finance
Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2022
-
July 15, 2022
Corporate
PDF310 KB
Nippon Shinyaku Selected as a Constituent of the FTSE Blossom Japan Sector Relative Index, a New ESG Index
-
May 31, 2022
R & D
PDF240 KB
VILTEPSO® (viltolarsen): Long-Term Efficacy and Safety Data Published in the Journal of Neuromuscular Diseases
-
May 30, 2022
R & D
PDF254 KB
Orphan Drug Designation granted to NS-87
-
May 17, 2022
Corporate
PDF241 KB
Nippon Shinyaku Provides Assistance to Ukraine
-
May 11, 2022
Management & Finance
Outline of Consolidated Financial Results for the Year Ended March 31, 2022
-
March 28, 2022
Pharmaceuticals
PDF285 KB
Marketing approval of MonoVer for I.V. injection 500mg/1000mg by MHLW for the treatment of iron deficiency anemia
-
March 17, 2022
R & D
PDF260 KB
The result of an Investigator-Initiated Clinical Trial (First In Human trial) of NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy
-
March 11, 2022
R & D
PDF259 KB
The result of an Investigator-Initiated Clinical Trial (First In Human trial) of NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy
-
March 07, 2022
Pharmaceuticals
PDF338 KB
Filing of Humanized Anti-CD20 Monoclonal Antibody Gazyva for Additional Indication of Chronic Lymphocytic Leukemia
-
February 10, 2022
Management & Finance
PDF547 KB
Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2021
-
January 26, 2022
Corporate
PDF270 KB
Nippon Shinyaku Establishes a Local Subsidiary in Tianjin, China
-
January 25, 2022
Pharmaceuticals
PDF245 KB
Nippon Shinyaku and Capricor Therapeutics enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in US
